Trials / No Longer Available
No Longer AvailableNCT03492489
Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
An Open-Label, Expanded Access Protocol of Cemiplimab in Patients With Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Who Are Not Candidates for Surgery
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The objective of this program is to provide access to cemiplimab (REGN2810) to patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for surgery prior to cemiplimab (REGN2810) being commercially available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cemiplimab | Intravenous (IV) administration |
Timeline
- First posted
- 2018-04-10
- Last updated
- 2019-08-01
Source: ClinicalTrials.gov record NCT03492489. Inclusion in this directory is not an endorsement.